|Chemical and physical data|
|Molar mass||142.5 kg/mol|
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029. In April 2017, Bayer terminated its option to license vanticitumab.
Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.
- "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)
- Finally, targeted therapies for triple-negative breast cancer. June 2016
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|